Epygenix Therapeutics Announces Appointment of Darren Cline as CEO
Mar 15, 2022
Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy, announces the appointment of Darren Cline as President and Chief Executive Officer and also Director of the Board. Mr. Cline will succeed Hahn-Jun Lee, M.Sc., Ph.D., who will continue serving on the Board of Directors and working as a transitionary advisor to the new CEO.
Mr. Cline is a seasoned pharmaceutical industry executive with an over-30-year track record of building key commercial organizations and functions. He is continuing his commitment to support patients and families of rare genetic epilepsies. "We are very excited for Darren to join our team, which will bring immediate synergies and be a critical catalyst for our commercialization efforts in highly unmet, rare epilepsy areas," said Alex Yang, JD, LLM, Chair and Executive Director of the Board at Epygenix.
Before joining Epygenix, Mr. Cline was most recently the US Chief Commercial Officer at GW Pharmaceuticals, where he led the successful commercialization of Epidiolex for rare epilepsies, which helped lead to the company's $7.2 billion acquisition by Jazz Pharmaceuticals in 2021. Before that, he was Executive Vice President, Commercial at Seagen, where he was responsible for the commercialization of ADCETRIS in the United States and Canada. Mr. Cline also held commercial leadership roles at Intermune, Alexion Pharmaceuticals, and Amgen. He is currently a member of the Pyxis Oncology Board of Directors and was formerly on the Stemline Therapeutics Board of Directors.
"Darren will add significant value to Epygenix with his seasoned experience in the commercialization of Epidiolex. He will lead the growth of the company from the clinical to commercial stage. Epygenix greatly welcomes him on board," commented Hahn-Jun Lee, M.Sc., Ph.D., a co-founder and Executive Director of Epygenix's Board.
"Darren knows the rare epilepsy disease space intimately and his established relationships in this space will open new opportunities for Epygenix. I am confident Darren's leadership will help bring safe and effective therapies to our patients," said Scott Baraban, Ph.D., a co-founder, Chair of the Scientific Advisory Board and Director of the Board at Epygenix.
"I am proud and honored to join Epygenix," said Mr. Cline. "The company has an extraordinary opportunity to leverage its unique platform to bring transformational therapies to patients who live with rare genetic epilepsies. I look forward to leading the company as it transitions into its next phase of clinical development and future commercialization."
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable forms of genetic epilepsy in childhood, such as Dravet Syndrome. Epygenix is currently focused on developing EPX-100, EPX-200, and EPX-300. These drug candidates abolish convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model, which mimics the human pathology. For more information, please visit www.epygenix.com.
Media Contact
Andrew O
Press Release Service by Newswire.com
Original Source: Epygenix Therapeutics Announces Appointment of Darren Cline as CEO
More News
Searing Elon Musk Film Nears U.S. Release Amid Overseas Concerns
Alex Gibney’s “Musk” will arrive in United States theaters next month. Universal says it remains committed to releasing it overseas but has yet to set dates.
Trump Seeks ‘Made in U.S.A.’ Labels on Beef as Import Rule Angers Ranchers
The Agriculture Department hopes Americans will pay more for U.S. beef, in an attempt to appease ranchers upset over increased, cheaper imports.
World Bank Courts Private Financing Amid Global Debt Burden
The World Bank president, Ajay Banga, has worked to make the development institution a magnet for private capital as donor nations face budget constraints.
Trump Blasts the Fed But Spares Kevin Warsh After Interest Rate Hike
The president blasted the rest of the Fed — and kept up his demand for a cut — but spared Fed Chairman Kevin M. Warsh from the criticism.
Mixed feelings from consumers as electricity discount to be given to NI households
The one-off £63 reduction in electricity bills will be applied from next month.
Warm words on Canada's EU 'associate membership' but no guarantees
There is no certainty that the idea will ever get off the ground, let alone become a blueprint for other countries, writes the BBC's Katya Adler.
Steve Bannon and Bernie Sanders Condemn Tech ‘Oligarchs’ and Demand A.I. Reforms
At an event in Washington, partisanship took a back seat as elected officials, religious leaders, parents and artists called for reining in artificial intelligence.
Barclays workers ask for more money to return to the office
Unite union, which represents 36,000 Barclays staff, calls for a one-off payment to offset increased travel and childcare costs.
Interest rates held but Bank signals rise if energy prices stay high
Rates are held for the sixth time in a row but the Bank of England says high energy prices make a future rise more likely.
Trump’s Latest Threats Loom Over Fed’s Interest Rate Decision
This month, the president threatened to halt a broad swath of trade if interest rates were not cut, a possibility he resurfaced on Wednesday.
Fed Raises Rates in First Major Step by Warsh to Contain Inflation
The Federal Reserve’s first increase to interest rates since July 2023 comes less than two months before the midterm elections.
Global Economy Is Running Out of Wiggle Room
Many countries blunted the most painful effects of the energy shock from the war in Iran. But prices remain elevated and risks are multiplying.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.